-
Mashup Score: 0Addition of Venetoclax to Lenalidomide and Rituximab Therapy for Patients With Previously Untreated MCL - 6 month(s) ago
Kami J. Maddocks, MD, discusses results from a single-arm study on the addition of venetoclax to a lenalidomide and rituximab regimen for patients with previously untreated mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 250th Year of Publication: Progress in Rheumatology During the 2010s - 7 month(s) ago
In this edition of The Journal of Rheumatology , I will be bringing to your attention the following 6 articles from the 2010s that had, and continue to have, a significant impact in rheumatology. Although I usually choose 3 papers, I have chosen 6 that can be grouped into 3 categories. The first category has a single paper that describes a modification of the American College of Rheumatology (ACR) classification of fibromyalgia (FM),1 the second category contains 2 papers on the use of the internet and social media in rheumatology,2,3 and the third contains 3 papers on long-term outcome studies in rheumatoid arthritis (RA).4-6 The first paper I wish to bring to your attention is “Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia” by Wolfe et al. … Address correspondence to Dr. E.D. Silverman, Editor-in-Chief, The Journal of Rheumatology, 365 Bloor Street East, Suite 901, Toronto
Source: www.jrheum.orgCategories: Latest Headlines, RheumatologyTweet-
50th Volume Reprint Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years 📰 https://t.co/WlKRndLtfO #longterm #rituximab #rheumatoidarthritis https://t.co/xAlrctsEJD
-
-
Mashup Score: 1
Patients with new or relapsing granulomatosis with polyangiitis or microscopic polyangiitis should receive rituximab over cyclophosphamide, according to new recommendations from the Pan American League of Associations for Rheumatology.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Patients with new or relapsing granulomatosis with polyangiitis or microscopic polyangiitis should receive #rituximab over cyclophosphamide #RheumTwitter https://t.co/PsrsmjCYIM
-
-
Mashup Score: 150th Year of Publication: Progress in Rheumatology During the 2010s - 7 month(s) ago
In this edition of The Journal of Rheumatology , I will be bringing to your attention the following 6 articles from the 2010s that had, and continue to have, a significant impact in rheumatology. Although I usually choose 3 papers, I have chosen 6 that can be grouped into 3 categories. The first category has a single paper that describes a modification of the American College of Rheumatology (ACR) classification of fibromyalgia (FM),1 the second category contains 2 papers on the use of the internet and social media in rheumatology,2,3 and the third contains 3 papers on long-term outcome studies in rheumatoid arthritis (RA).4-6 The first paper I wish to bring to your attention is “Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia” by Wolfe et al. … Address correspondence to Dr. E.D. Silverman, Editor-in-Chief, The Journal of Rheumatology, 365 Bloor Street East, Suite 901, Toronto
Source: www.jrheum.orgCategories: Latest Headlines, RheumatologyTweet-
50th Volume Reprint Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials 📰 https://t.co/WlKRndLtfO #jrheum50 #reprints #rituximab #rheumatoidarthritis https://t.co/enG7HYuaS1
-
-
Mashup Score: 18How to Treat Chronic Lymphocytic Leukemia (CLL) with Dr. Jeff Sharman – ONC Brothers - 7 month(s) ago
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and…
Source: oncbrothers.comCategories: Latest Headlines, Partners & KOLsTweet-
w/@jeff_sharman we🗣️SoC for #CLL & key📝 to 🔍 in the community: - Fixed⏰Rx vs. BTKi - #Obinutuzumab/#Rituximab - #Venetoclax management Full discussion: - https://t.co/YuEQBXnZHX - Also on the “Oncology Brothers” podcast #Leusm #HemeTwitter #MedTwitter #OncTwitter https://t.co/n76iML2HOm
-
-
Mashup Score: 0First-Line Subcutaneous Rituximab May Increase PFS in Low Tumor Burden FL | ASH Clinical News | American Society of Hematology - 8 month(s) ago
Katie Robinson is a medical writer based in New York. In patients with low tumor burden follicular lymphoma (FL), subcutaneous (SC) rituximab incr eased progression-free survival (PFS) and complete response (CR) rates when used in induction followed by short maintenance compared with conventional intravenous (IV) induction without maintenance, according to a study published in the Journal of Clinical Oncology. However, high rituximab exposure during the first three months of treatment initiation was the
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
In patients with low tumor burden #follicularlymphoma, the use of subcutaneous #rituximab increased PFS and CR rates when used during induction followed by short maintenance compared with conventional IV induction without maintenance https://t.co/DaeUs4EsQ5
-
-
Mashup Score: 0BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma - 8 month(s) ago
At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 European Hematology Association #EHA Congress, Vincent Ribrag, MD, debated whether #BTK inhibitors should be combined with other therapies, such as #bendamustine and #rituximab, as first-line treatment for patients with #MCL. https://t.co/aAvq27JhxU @EHA_Hematology https://t.co/72lsjSd0Kd
-
-
Mashup Score: 5
The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of front-line, fixed-duration venetoclax and rituximab (VenR) in combination in young (≤65 years), fit patients with chronic lymphocytic leukemia and unmutated IGHV and/or TP53 disruption. Treatment consisted of the venetoclax ramp-up, six monthly courses of the VenR combination, followed by six monthly courses of venetoclax as a single agent. A centralized assessment of minimal residual disease (MRD) was performed by allele-specific oligonucleotide polymerase chain reaction assay on the peripheral blood and bone marrow at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range, 38-65), 96% had unmutated IGHV, 12% had TP53 disruption, and 4% had mutated IGHV with TP53 disruption. The overall response rate at the EOT was 94.7%, with a complete remission rate of 76%. MRD was und
Source: haematologica.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read here the promising results of the GIMEMA phase II LLC1518 VERITAS trial investigating front-line, fixed-duration #venetoclax and #rituximab (VenR) combination in #CLL. https://t.co/csh3wg85cl https://t.co/rJ7A3iaACT
-
-
Mashup Score: 1Validate User - 9 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A recent study has revealed that patients with #autoimmune #cytopenias had longer durations of response after induction treatment with #rituximab when it was continued as maintenance therapy compared with no post-treatment rituximab maintenance https://t.co/e9mF4FS2Hg
-
-
Mashup Score: 0Rituximab superior to cyclophosphamide in GPA remission induction - 9 month(s) ago
In patients with granulomatosis with polyangiitis, those who start induction therapy with rituximab are more likely to achieve remission compared with those who begin cyclophosphamide, according to data published in JAMA Network Open.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
🟢 The latest @HealioRheum and @RheumOnePagers collaboration is here 🟢 In patients with #GPA, those who start induction therapy with #rituximab are more likely to achieve remission #RheumTwitter @MithuRheum 📖Read more: https://t.co/kJDcwMUUaX https://t.co/WFOSCCu1pF
-
In this video, Kami J Maddocks, MD, discusses the results of a multicenter single-arm study that explored the addition of #venetoclax to #lenalidomide and #rituximab treatment for patients with previously untreated #MCL. Learn more: https://t.co/sqXKHEqdHY @kmaddmd #MedTwitter https://t.co/bYfGsyhWKm